$3.93
-0.63 (-13.82%)
Open$4.71
Previous Close$4.56
Day High$4.77
Day Low$3.93
52W High$19.15
52W Low$8.60
Volume—
Avg Volume453.4K
Market Cap6.00M
P/E Ratio22.52
EPS$0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+437.7% upside
Current
$3.93
$3.93
Target
$21.13
$21.13
$13.63
$21.13 avg
$23.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.00M | 1.99M | 1.61M |
| Net Income | -74,230 | -69,635 | -62,110 |
| Profit Margin | -3.7% | -3.5% | -3.9% |
| EBITDA | -116,342 | -139,946 | -107,891 |
| Free Cash Flow | -67,743 | -57,560 | -72,298 |
| Rev Growth | +11.8% | +24.3% | -3.3% |
| Debt/Equity | 0.69 | 0.66 | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |